About
About Shionogi
Who we are
Heritage
Global affiliates and locations
Shionogi BV - tax strategy
Transparency
Investor Relations
Grants and Donations
Sustainability
Innovation
Innovation
Our areas of focus
Our Partners
Drug Discovery
News
Investors
Careers
Contact
Europe
Worldwide
HOME
News
2023
04
ECCMID 2023 Shionogi Announces Real-World Evidence Demonstrating the Efficacy of Fetcroja® (cefiderocol) Against Some of the Most Difficult-to-Treat Gram-Negative Bacterial Pathogens
Release
Medical News
2023/04/17
ECCMID 2023: Shionogi Announces Real-World Evidence Demonstrating the Efficacy of Fetcroja® (cefiderocol) Against Some of the Most Difficult-to-Treat Gram-Negative Bacterial Pathogens